Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Depreciation & Amortization (CF) (2016 - 2025)

Aptevo Therapeutics' Depreciation & Amortization (CF) history spans 11 years, with the latest figure at $49000.0 for Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) fell 41.67% year-over-year to $49000.0; the TTM value through Sep 2025 reached $230000.0, down 42.07%, while the annual FY2024 figure was $352000.0, 37.92% down from the prior year.
  • Depreciation & Amortization (CF) for Q3 2025 was $49000.0 at Aptevo Therapeutics, roughly flat from $49000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $299000.0 in Q2 2021 and bottomed at $49000.0 in Q2 2025.
  • The 5-year median for Depreciation & Amortization (CF) is $150000.0 (2023), against an average of $164368.4.
  • The largest annual shift saw Depreciation & Amortization (CF) decreased 1.67% in 2021 before it plummeted 46.15% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $256000.0 in 2021, then plummeted by 37.11% to $161000.0 in 2022, then fell by 27.95% to $116000.0 in 2023, then tumbled by 38.79% to $71000.0 in 2024, then tumbled by 30.99% to $49000.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Depreciation & Amortization (CF) are $49000.0 (Q3 2025), $49000.0 (Q2 2025), and $61000.0 (Q1 2025).